By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today reported $413,000 in revenues for the third quarter, led by licensing revenues.

In the year-ago period when the Austin, Texas-based molecular diagnostics company was in Chapter 11, it posted no revenues.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.